Cutaneous
Cutaneous
Lymphoma
Lymphoma
Foundation:
Foundation:
Promoting
Making sure
awareness
each person
and education,
with cutaneous
advancing
lymphoma
patientgets
care,the
and
best
facilitating
care possible
research.
Forum
www.clfoundation.org
Winter/Spring 2007
Ground-breaking Quality of Life Research
From the Executive Director ........ 2
From the President:
Diving into the Board .................... 3
A Changing Board ....................... 3
Giving Made Easy with the
Pension Protection Act of 2006 ... 4
Clinical Trials .................................4
Ask the Expert ...............................5
International Spotlight for
T-Cell Lymphomas ........................6
Cutaneous Lymphoma
Patient Educational Fourms ......... 7
Run for the CTCL Cure
There was no race for the cure
of cutaneous T-cell lymphoma--until
now.
Running in the Long Island
10k 1/2 Marathon in May, is a
patient who is raising money in support of the Cutaneous Lymphoma
Foundation. Scott, a 24-year-old
college grad, has already raised over
$11,000, with a goal of $15,000. All
of this money will be donated to the
Cutaneous Lymphoma Foundation.
To track Scott’s progress and
donate, please visit www.firstgiving.
com/scott.
Please join us in supporting
Scott in his goal!
D
In March 2005, the survey was sent
r. Marie-France Demierre of
to the Foundation’s mailing list, as
Boston University School of
well as made available online, on the
Medicine, Director of Skin Oncology,
Foundation website. All anonymous
collaborated with the Cutaneous
responses from the completed surveys
Lymphoma Foundation on an
(from the paper and online versions)
extremely important study, that of
were compiled by Dr. Demierre and
our patients’ health-related quality of
her team at Boston University. The
life. Health-related quality of life is a
data was analyzed
multidimensional
and the results were
term that includes
“We physicians need
recently published
the physical, functo do a better job
in the important
tional, psychologiwhen we care for our
peer-reviewed jourcal, social health,
patients. We need
nal CANCER. The
and well-being
to acknowledge the
article was titled
of the individual.
emotional aspect
“Significant Impact
Dr. Demierre has
and social impact of
of Cutaneous Tbelieved for several
the disease on our
cell Lymphoma on
years that cutanepatients.”
Patients’ Quality
ous T-cell lymphoof Life: Results of
ma patients’ healtha 2005 National
related quality of
Cutaneous Lymphoma Foundation
life was often overlooked in patient
care. Her own experience taught
Survey.”
her that unless one could improve
“An impressive 68% of all members
patients’ sleep or itch, one would not
with cutaneous T-cell lymphoma combe able to completely improve their
pleted the survey. While the majority
had early stage mycosis fungoides, the
health.
responses were compelling with 94%
In collaboration with Ms. Judy
reporting that they worried about the
Jones, Executive Director and coseriousness of their disease and 80%
founder of the Foundation and with
worrying about dying from the disthe approval of the Board of the
ease” said Dr. Demierre. Other findCutaneous Lymphoma Foundation,
ings were the following: 94% of memshe and her colleagues developed a
bers who responded were bothered
comprehensive survey that addresses
by skin redness, 88% by pruritus, and
all the dimensions of health-related
the extent of symptoms affected the
quality of life. The survey’s goal was
choice of clothing in 63%. For most,
to evaluate patients’ perspectives
the disease had a functional impact,
regarding the impact of cutaneous
making them tired or affecting their
T-cell lymphoma and its treatment
sleep. Sixty-two percent felt that
on their lifestyle, occupation, emotheir disease made them unattractive.
tional health, and social condition.
QOL continued on page 4
Cutaneous Lymphoma Foundation
Forum
The newsletter of the Cutaneous Lymphoma Foundation
ALL RIGHTS RESERVED
DESIGNER & EDITORIAL DIRECTOR
Amanda L. J. Kik
MEDICAL EDITOR
Stuart Lessin, M.D.
Cutaneous Lymphoma Foundation is a 501(c)(3)
non-profit organization. Donations are tax deductible
to the extent allowed by law.
SCIENTIFIC ADVISORY BOARD
Thomas Anderson, M.D. University of Michigan
Kevin Cooper, M.D. Case Western Reserve University
Madeleine Duvic, M.D. MD Anderson Cancer Center
Francine Foss, M.D. Yale University School of Medicine
Lars French, M.D. Geneva Medical Center
Sam Hwang, M.D., Ph.D. National Institutes of Health
Robert Knobler, M.D. University of Vienna
Thomas Kupper, M.D. Brigham and Women’s Hospital
Liliane Laroche, M.D. University of Paris
Stuart Lessin, M.D. Fox Chase Cancer Center
Sue McCann, MSN, RN University of Pittsburgh Medical Center
Lauren Pinter-Brown, M.D. UCLA Medical Center
Porcu Pierluigi, M.D. Ohio Sate University
David Ramsay, M.D. New York University
Alain Rook, M.D. University of Pennsylvania
Steven T. Rosen, M.D. Northwestern University
Marianne Tawa, MSN, RN, ANP Dana Farber Cancer Institute, Boston
Martin Weinstock, M.D., Ph.D. Brown University
Sean Whittaker, M.D., MRCP Guys & St. Thomas Hospital
Lynn Wilson, M. D., MPH Yale University School of Medicine
Cutaneous Lymphoma Foundation
PO Box 374
Birmingham, MI 48012-0374
telephone: (248) 644-9014
fax: (248) 644-9014
email: [email protected]
www.clfoundation.org
Forum is published by the
Cutaneous Lymphoma Foundation.
Because each person’s body and response to treatment is
different, no individual should indulge in self-diagnosis
or embark upon any course of medical treatment that is
described in Forum without first consulting with his or
her physician.
Cutaneous Lymphoma Foundation is not responsible for
the medical care or treatment of any individual.
2
From the Executive Director
F
or those of you that have been
around a while, you may notice
a new picture of the executive
director. I really enjoyed not getting
any older for the past seven years and
decided it was time to “get real.” Now,
as I travel around the country attending
the educational forums, you’ll recognize
me.
I am so excited about our Cutaneous Lymphoma Patient
Educational Forums this year. We are in the process of planning ten of these events across the United States and will also
be in Calgary, Canada this fall. This is an ambitious program,
and we’ve had really good feedback on how valuable they are
to patients and their families. The success of our Educational
Forums depends on you. I hope you will watch for us coming to
your area and attend. We will post information about upcoming
events on our website as we obtain firm dates and locations.
We started off this year with the usual flurry of activity surrounding the many meetings in February: American Academy
of Dermatology Annual Meeting, Dermatology Nurses’
Association Annual Convention, Coalition of Skin Diseases
Annual Meeting and the International Society of Cutaneous
Lymphomas Workshop on Sezary Syndrome.
There is a lot of exciting research being done in the field
of CTCL both in the basic sciences and in treatment options
through clinical trials. Both types of research are necessary to
both give us additional treatment options as we look for the
causes and cure. We will be reporting on this research in future
issues.
Other cancers have golf outings, biking, running and walking events, which I fully support. This is necessary in providing
funding for cancer in general, but there was no one running for
cutaneous lymphomas…until now.
Scott had just graduated from college when he was diagnosed with CTCL. For the past two years he has been undergoing treatment and unless someone finds a cure, will continue
treatment throughout his life. He has decided to run the Long
Island 10k Half Marathon to increase awareness of CTCL
and raise funding for the Cutaneous Lymphoma Foundation.
We will use this money to continue to increase awareness and
encourage research in the field.
To track Scott’s progress and donate, please visit
www.firstgiving.com/scott. One step at a time--that’s the way
the Cutaneous Lymphoma Foundation
has evolved. Now, Scott is taking us-one step at a time--to find a cure. Join
us in supporting Scott in his goal.
Forum, Winter/Spring 2007
From the President: Diving into the Board
I
n November
2002, a
group of people
received an
email from Judy
Jones with an
invitation to
attend a meeting. It began,
“Plans were put in motion for this meeting over three years ago, and I’m excited
that it is finally, actually going to be a
reality. You are going to be involved
in taking the Mycosis Fungoides
Foundation to the next level. Some of
the decisions we make at this meeting
will be the basis of setting the direction
of the MFF in the years to come.”
The nine members of the newly created Board of Directors, mostly strangers to one another, would face dual
challenges in the years following that
meeting:
Running the foundation, and at
the same time learning a new job.
Although some of us had experience
serving on boards and committees,
starting a foundation and board from
scratch was entirely different.
Forming our board’s “team”: getting to
know one another, and then repeating
the process with new board members.
Who were these people, what skills
did they have, who would do which
job, and how would we learn to work
together?
Five board members have left and
been replaced during the four years since
that initial meeting. Despite the turnover, the board has accomplished quite
a bit of its own “busy work” – things that
don’t get much attention but are necessary nonetheless:
• We rewrote the bylaws of the
foundation to reflect what we
learned as we grew and changed.
• We wrote formal policies related to
finance, conducting board business,
conflict of interest, and other topics
as they arose.
• We developed an annual budget
and associated procedures,
including holding a formal
annual meeting.
• We had the foundation’s financial
records and processes audited by
a CPA.
• We participated in a facilitatorled retreat where we redefined and
recommitted to our mission and
vision for the foundation.
• We recruited new board members
along the way to replace those who
had to leave.
• We established formal terms of
office and Officer positions for
the board.
• We acquired part-time staffers
(Amanda Kik and Holly Priebe)
who helped us accomplish all this.
A Changing Board
P
lease join us in welcoming the talent of Leora
Lowenthal to the Cutaneous Lymphoma
Foundation Board of Directors and wishing Frank
Strobl all the best as he retires from his years of service for
the Board.
Leora is a Senior Social Worker at the NYU Cancer
Institute in New York City. Her role there includes the
provision of counseling, case management, and the development of educational events and materials. In addition, Leora
runs an online support group for CancerCare and is currently a state representative for the Association of Oncology
Another outcome of the board’s
work has been to relieve Judy Jones,
the Cutaneous Lymphoma Foundation
founder and executive director, of many
administrative duties she has been
performing as a volunteer (that’s right,
UNPAID).
Looking to its future, the board
would like to expand its role in foundation activities, learn more about the people we represent in the foundation, find a
way to put eager volunteers to work, and
continue to relieve Judy Jones of administrative work so she can focus on what
she enjoys and does best: supporting
people with cutaneous lymphoma. We’ll
do all that while we continue and expand
the work we do for the people served by
the Cutaneous Lymphoma Foundation.
The Board of Directors meets
two or three times a year face-to-face
and conducts conference-call meetings
each month between face-to-face
meetings. To get information about
meetings please contact Amanda Kik
at [email protected]. To learn
more about the people on your Board
of Directors, please take a look at the
Cutaneous Lymphoma Foundation
website: www.clfoundation.org and
click on “Who we are.”
Social Work. She received a BS
from Cornell University, an MSW
from Boston University and completed a post-graduate certificate
in the study of bioethics. In the fall
of 2007 she intends to begin working toward her Master’s in Public
Administration with a focus on
Leora Lowenthal
Health Policy and Management.
Frank Strobl left the Board
at the end of 2006, and we will miss his insight and humor
as he moves on to other projects.
Thank you, Leora and Frank, for your service! ✹
3
Cutaneous Lymphoma Foundation
Giving made easy with the Pension Protection Act of 2006
Clinical Trial Evaluates
the Protective Effects of SoyBased Ointment
The Mount Sinai School of Medicine
Department of Dermatology is conducting a clinical trial to evaluate the protective
effects of a soy-based ointment (genistein) on
PUVA-treated Mycosis-Fungoides patients.
The ointment is not FDA approved, but
previous research indicates that it may offer
protection against skin-damage caused by
PUVA therapy.
You may qualify for the study if you
have Mycosis Fungoides, are 18 years or
older, and your physician believes that you
are a candidate for PUVA therapy. The
study will be a 12-week study for subjects
receiving PUVA therapy 2-3 times a week.
A total of two 2 mm punch biopsies at the
beginning and four 2 mm punch biopsies at
the end of the study will need to be collected
during the study period. Skin examination
and photographs of lesions will also be
taken at week 1, week 4, week 8, and week
12. Subjects will be asked to apply genistein
ointment at the time of psoralen injection
before every UVA-therapy session (approximately 90 minutes prior to UVA exposure).
IRB approved under the GCO # 060929 from 10/11/2006 until 9/18/2007.
For more information, please contact Paru at (212) 241-6033 or e-mail paru.
[email protected].
The Pension Protection Act of 2006 has provided a unique opportunity for
individuals to donate to their favorite qualified charity from their Traditional or
Roth IRA.
You may qualify to contribute funds from the IRA if:
1. you are 70 1/2 or older during 2006 or 2007
2. the gift is made on or before December 31, 2007
3. the gifts do not total more than $100,000 per year
4. the funds must be transferred directly from the IRA to the qualified charity
We encourage you to consult with your tax advisor to determine if taking
advantage of opportunities in this legislation is in your best interest. What a
great way to see your desire to help these qualified charities come to life.
If you suffer from mycosis fungoides, there may be a new treatment
available to you in a clinical trial. Genmab is currently conducting a study
throughout the United States with zanolimumab (HuMax CD4) to treat patients
with mycosis fungoides. The study consists of 12 weekly IV infusions and a followup period. During the study all patients will be assessed on a routine basis for
safety and efficacy. If you qualify for the study, you will receive all evaluations and
procedures related to the study at no cost.
You may qualify for the study if you have had a biopsy taken that shows that
you have mycosis fungoides, you have received at least 2 other therapies, one of
which has been Targretin®, but you have not had any benefit of the treatment or
you have experienced side effects, are at least 18 years of age, and signed informed
consent.
If you are interested in hearing more about this study and finding the
nearest study center please contact Reynold Daniel at 1-866-887-1291 or
email [email protected] .
QOL continued from front page
Although 85% felt that their treatment made their disease
more manageable, 61% reported feeling financially burdened
by their disease.
Dr. Demierre and her team also performed a special
analysis of all the questions and of their relevance. A key
finding was that 5 important themes stood out, those of role
functioning, health distress, treatment satisfaction, symptoms of disease, and emotional well-being. Furthermore,
these 5 themes could differentiate those members with early
stage disease as opposed to those members with later stage
disease. In other words, while all participants reported a
significant impact of CTCL on their health-related quality
4
of life, those identifying themselves as having more advanced
disease had an even more significant impact on their healthrelated quality of life. “This study was humbling. I was
shocked to see how for almost all responding members,
CTCL had a major impact on their quality of life. We physicians need to do a better job when we care for our patients.
We need to acknowledge the emotional aspect and social
impact of the disease on our patients. We should strive to
improve their functioning,” said Dr. Demierre. She further
added that physicians may not fully appreciate the financial
burden that the disease is placing on patients.
QOL continued on next page
Forum, Winter/Spring 2007
Ask the Expert
“Ask the Expert”
is a regular feature
in Forum, where
you can have your
questions answered
by an expert. This
issue, questions
are answered
by Dr. Thomas Anderson, Associate
Professor and Director of Photo Medicine
for the Department of Dermatology at the
University of Michigan Medical Center
in Ann Arbor, Michigan. He is the CoDirector of the Multidisciplinary Cutaneous
Lymphoma Program.
D
ear Expert,
How does PUVA work? What’s the
difference between the effects of UVA
and UVB? When I do PUVA with
Psoralen is this considered
chemotherapy?
PUVA chemotherapy is one of the
most effective treatments for cutaneous
T-cell lymphoma limited to the skin
(Stage 1A and 1B). PUVA is an acronym
for psoralen plus UVA photo radiation.
It is sometimes called photo-chemo
therapy because it is the combination of
ultra violet light plus chemical medication that is not active without the light.
This has no relationship to cytotoxic
chemotherapy, often used for systemic
lymphoma or late stages of cutaneous
T-cell lymphoma. Most dermatologists
treating patients with cutaneous T-cell
lymphoma wish to avoid using cytotoxic
chemotherapy, as one of the major side
effects is systemic immunosuppression
which can render a patient more susceptible to serious infection. Serious infection can be the cause of death in patients
with end stage progressive lymphoma.
A therapeutic goal is to avoid treatments
that produce systemic immunosuppression.
Although PUVA may cause limited
cutaneous immunosuppression, it does
not affect the entire immune system and
is very effective in killing lymphoma cells
in the skin. In addition, there is evidence
which supports a theory that PUVA
may also stimulate the patients’ immune
system to fight the cutaneous lymphoma.
This is one of the major theories of how
extra-corporal photopheresis (or PUVA
of the blood) Sézary Syndrome works.
There are three major forms of
phototherapy used to treat cutaneous
disease. Most dermatologists have
experience using this form of therapy in
the treatment of psoriasis but they work
for stage 1 cutaneous lymphoma equally
well. The oldest form of phototherapy,
Broadband UVB, is very effective for
psoriasis but not as effective for cutaneous T-cell lymphoma. A newer form
of UVB therapy, called Narrow Band
UVB, appears to be very effective for
psoriasis as well as patch stage or thin
(early) cutaneous T-cell lymphoma.
Thicker plaque stage disease responds
best to PUVA therapy. It may also
respond to Narrow Band UVB therapy
when combined with a systemic retinoid
(acetretin or bexarotine). In general,
most patients with Stage 1 disease can
do quite well on a course of Narrow
Band UVB phototherapy or PUVA
photo-therapy often obtaining clinical
remissions that can last from months to
years after a course of treatment.
The difference between UVA and
UVB is mainly the depth of penetration
of this form of ultra-violet light phototherapy. Broadband UVB penetrates
the shallowest and PUVA or UVA penetrates the deepest, with Narrow Band
UVB being intermediate.
One of the major side effects of
ultra-violet photo-therapy is the risk of
development of skin cancer. We know
that excessive natural sunlight over a
lifetime increases the chances for skin
cancer. We also know that greater than
200 PUVA treatments add to that risk.
There is medical evidence to suggest
that UVB phototherapy does not significantly add to the risk of skin cancer
over natural exposure to sunlight over
a lifetime. In all cases, the types of skin
cancer that develop in patients who
have been treated with phototherapy are
easily cured if caught early. Therefore,
it is important for patients who receive
photo-therapy to be followed closely by a
dermatologist and have any unusual skin
growths removed. We also recommend
avoiding sun exposure while getting
phototherapy treatment.
✹
QOL continued from previous page
“I am personally indebted to all the CTCL members who took the time to complete the survey. Their
responses and input were so important and they will
shape the future care of our patients,” she concluded.
Her dream is that physicians will routinely ask healthrelated quality of life questions of their patients about
their functioning, and that clinical trials will begin to
consistently address what may be the most important
to patients, their quality of life. She is already working
on these next challenges. ✹
For Physicians: 1st Annual Symposium on Cutaneous Lymphomas
Held at Moffitt Cancer Center in Tampa, Florida, this Symposium will
review the most recent data on diagnosing cutaneous lymphoma based
on the WHO/EORTC consensus classification along with providing
the most common subtypes of cutaneous lymphomas. The conference is
a forum for experts to discuss the approved and investigational agents
and modalities used to treat patients with this disease. The conference is
structured to provide the opportunity to interact with the faculty and each
other. For more information, visit: www.moffittcancercenter.org and
click on Events Calendar .
5
Cutaneous Lymphoma Foundation
International Spotlight for T-Cell Lymphomas
Reported by Dr. Steven Horwitz,
Memorial Sloan-Kettering
Cancer Center
T
his past October an exciting
and unprecedented meeting
took place in Bologna, Italy.
As part of an ongoing series of academic meetings, the Societa Italiana
di Ematologia (Italian Institute of
Hematology and Oncology) organized
this year’s meeting around addressing
the issues of understanding and treating
T-cell lymphomas. Entitled “It’s Time
to take Care of T-cell Lymphomas,” the
conference brought together over 50
faculty members and several hundred
attendees from around the world to
discuss, teach, learn, and share their
emerging data and new approaches
to this group of uncommon diseases.
Investigators from eleven countries
in North America, Europe, and Asia
presented their findings. While there
have been important small conferences
designed as think tanks to approach the
problems of T-cell lymphoma, this conference is the largest and most comprehensive to date.
The conference took place over
three days and was divided into sections:
State of the Art on T-cell Lymphomas,
Peripheral T-cell Lymphomas (PTCL)
Morphology and Biology, PTCL
Innovative Treatments, CTCL
Morphology and Biology, CTCL
Innovative Treatments, From Mouse
Models to Prognostic Markers, When
and Which Aggressive Treatment?
Excellent lectures by Dr. Raymond
Liang from Hong Kong and Dr. Elaine
Jaffe reviewed the epidemiology and
pathogenesis of T-cell lymphomas
respectively. This was followed by representatives from the US, Europe, and
Asia reviewing their experiences and
“standard” approaches to these diseases.
Suprisingly similar approaches are used
throughout the world. This was fol-
6
lowed by new data and insights on the
molecular features of T-cell lymphomas.
Similarly excellent updates on histology,
as well as new data on the molecular
biology and gene expression profiling
was provided for the specific types of
CTCL.
New Therapies
The largest portion of the conference was dedicated to the development
of new or improved therapies both for
systemic and cutaneous T-cell lymphomas. An entire session was devoted to
the emerging role of histone deacetylase
inhibitors including lectures by Dr.
Owen O’Connor on SAHA (vorinostat),
Dr. Susan Bates on depsipeptide, and
Dr. Pierluigi Porcu on MS-275. These
drugs all appear to have important
therapeutic activity in both CTCL and
PTCL. Among the highlights specifically for CTCL, data were presented
on the optimal use of currently available
therapies including chemotherapies such
as gemcitabine and liposomal doxorubicin as well as the biologic therapies denileukin diftitox, interferon, bexarotene,
lenalidomide, and alemtuzumab. New
data were presented by Dr. d’Amore
from ongoing studies on the activity
of HuMax-CD4, an antibody used to
direct the immune system against the Tcells of CTCL. One of the hosts for the
conference, Dr. Pierluigi Zinzani, presented early results form his study using
bortezomib (a proteosome inhibitor
currently used for multiple myeloma and
mantle cell lymphoma) in cutaneous Tcell lymphoma. Dr. Francine Foss from
Yale University reviewed forodosine
as well as other new drugs for CTCL.
Other new drugs in development for
T-cell lymphomas included pralatrexate,
clofarabine, nelarabine, and anti CTLA4. There was an excellent review of our
most aggressive therapies by Dr. Onida
of Milan on the state of the art of stem
cell transplantation, both autologous
(self) and allogeneic (donor) for CTCL.
In the mouse model session, basic
science approaches as paradigms for
increasing our understanding of these
diseases in people were presented
including an outstanding lecture by
Dr. William Plunkett on approaches to
developing new therapies for T-cell lymphomas.
Overall, the meeting brought
together a international community of
physicians and scientists with both a
wide range of expertise and deep interest in studying T-cell lymphomas. The
number of new therapies on the horizon
and array of new approaches certainly
bodes well that we will continue to gain
a greater range of tools to treat these
diseases and improve the lives of people
with them.✹
Lymphoma Coalition
Worldwide Network of
Lymphoma Groups
The Cutaneous Lymphoma
is proud to be a member of the
Lymphoma Coalition that shares
the similar mission for lymphoma
as we do specifically for cutaneous
lymphomas. We have increased
our membership to 30 members
from 25 countries with the addition of Linfomas Argentina, Grupo
Linfoma Uruquay and the Polish
Lymphoma Association. The steering committee is comprised of members from Lymphoa Association,
UK, Lymphoma Research
Foundation, USA, Leukaemia and
Blood Foundation of New Zealand,
Lymphoma Support Ireland,
Lymphoma Foundation Canada
and ABRALE, Brazil.
Plans are underway for World
Lymphoma Awareness Day 2007,
on September 17th. There will be
events held around the world to
bring awareness about lymphoma
and the needs and rights of lymphoma patients.
Forum, Winter/Spring 2007
Cutaneous Lymphoma Patient Educational Forums
Hundreds of people with cutaneous lymphoma and their caregivers have benefitted from Cutaneous Lymphoma Patient
Educational Forums. Above left, an audience takes notes in Toronto. Above right, Amanda Kik moderates a panel of cutaneous lymphoma specialists at the Forum in New York City.
The Cutaneous Lymphoma Foundation Patient Education
Forums are the Foundation’s signature events and mechanism by which it carries out its mission. Patient Educational Forums provide exceptional opportunities for people
with cutaneous lymphoma to receive accurate information
about treatment options, access experts in the field and connect with other people with similar experiences.
Cutaneous Lymphoma Foundation Patient Education
Forums key features:
Half-day to day-long event
Held in cities throughout North America
Upcoming Patient Education Opportunities
Philadelphia, PA, June 30, 2007
Cutaneous Lymphoma Patient Educational Forum
San Francisco, CA, September 15, 2007
Lymphoma Workshop, presented with the Lymphoma
Research Foundation
Brooklyn, NY, October 12 – 14, 2007
North American Educational Forum on Lymphoma
Minneapolis, MN, November 3, 2007
Lymphoma Workshop, presented with the Lymphoma
Research Foundation
Boston, MA, Date TBA, 2007
Lymphoma Workshop, presented with the Lymphoma
Research Foundation
Professional and lay speakers
Los Angeles, CA, Date TBA, 2007
Cutaneous Lymphoma Patient Educational Forum
Format includes lectures, Q&A sessions and
small-group discussions
Pittsburgh, PA, Date TBA, 2007
10th Annual Jegasoth Support Group for CTCL
Objectives:
• Develop a better understanding of diagnostic tests.
• Learn about treatments available for different stages.
• Identify resources for treatment and support.
For more information, please visit www.clfoundation.org, email
[email protected], or call 248-644-9014.
Chicago, IL, Date TBA, 2007
Cutaneous Lymphoma Patient Educational Forum
Bottom left: Dr. Francine Foss talks about how photopheresis works • Bottom middle: Presenters from the Philadelphia Forum,
including (from left to right) Dr. Stuart Lessin, Dr. Ellen Kim, Dr. Frank Strobl, and Judy Jones • Bottom right: Presenters from the New
York City Forum, including (from left to right) Dr. Lynn Wilson, Dr. David Ramsay, Dr. JoAnn Latkowski, Dr. Kenneth Hymes, Judy
Jones, Dr. Francine Foss, Dr. Steven Horwitz, and Dr. David Straus
7
PO Box 374
Birmingham, MI 48012
NON-PROFIT
US POSTAGE PAID
BIRMINGHAM MI
PERMIT NO 265
Mark Your Calendar
Chicago, IL
Cutaneous Lymphoma Patient Educational
Forum
Date TBA, 2007
Minneapolis, MN
Lymphoma Workshop, presented with the
Lymphoma Research Foundation
November 3, 2007
Pittsburgh, PA
10th Annual Jegasoth Support Group for
CTCL
Date TBA, 2007
Brooklyn, NY
North American Educational Forum on
Lymphoma
October 12 – 14, 2007
Los Angeles, CA
Cutaneous Lymphoma Patient Educational
Forum
Date TBA, 2007
San Francisco, CA
Lymphoma Workshop, presented with the
Lymphoma Research Foundation
September 15, 2007
Boston, MA
Lymphoma Workshop, presented with the
Lymphoma Research Foundation
Date TBA, 2007
Philadelphia, PA
Cutaneous Lymphoma Patient Educational
Forum
June 30, 2007
These educational opportunities are made possible by
generous unrestricted educational grants from:
Platinum Sponsor: Ovation
Gold Sponsor: Therakos
Silver Sponsor: Gloucester
For more information about these free events, please
visit our website, www.clfoundation.org,
or email us at [email protected],
or call (248)644-9014